- Home
- products
- usa california
- drug design with structure based drug design
Show results for
Refine by
Drug Design With Structure Based Drug Design Equipment Supplied In Usa California
11 equipment items found
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). This is a disease with significant commercial opportunity as ...
Manufactured by:Advin Biotech, Inc. based in, CALIFORNIA (USA)
Our new iSplit Cup and POCiT cup are examples of Advin’s focus on innovative engineering that result in improvements in the drug testing field. These designs remove steps in the lab and/or reduce shipping costs and storage footprint without the need for handling sharps or extra components. Both cups have patents pending and are exclusively available from Advin ...
Manufactured by:Alfa Scientific Designs, Inc based inPoway, CALIFORNIA (USA)
ALFA’s reliability for speed and accuracy in point of care rapid tests is readily available in the configuration you need. Our Multi-Drug Urine Cassette Test formats vary to our customers’ ...
Manufactured by:Capricor Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Our core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. Since the initial publication in 2007, CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to ...
by:Vybion based inMonterey, CALIFORNIA (USA)
INT41 has received Orphan Drug Designation from the FDA for Huntington’s disease. IND enabling studies for INT41 Gene Therapy for Huntington’s disease are in place following a preIND meeting with the FDA in in February 2022 in response to the briefing book prepared by our consultants at Latham BioPharm, a world class consulting group based in Cambridge MA. ...
by:Valo Health, Inc. based inBoston, MASSACHUSETTS (USA)
Opal is the first end-to-end integrated drug discovery & development platform. Traditional, linear approaches to target discovery and drug development have created sub-optimized systems that are intrinsically disintegrated and ...
Manufactured by:Alkahest, Inc. based inSan Carlos, CALIFORNIA (USA)
One the key chronokine targets identified using Alkahest’s platform is eotaxin. Eotaxin is an immunomodulatory chemokine that is increased in normal aging as well as multiple diseases of aging. It has been implicated in Alzheimer’s disease, Parkinson’s disease, retinal diseases and other aging-related diseases that involve systemic inflammation, demonstrating effects both in the ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
Idiopathic pulmonary fibrosis [IPF] is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the disease progresses, the increased scarring leads to decreasing transfer of oxygen into the bloodstream, and ultimately, irreversible loss of lung function. The average life expectancy after an IPF diagnosis is 3-5 years.1 Because there is no cure and no therapy has been shown ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia ...
Manufactured by:Lineage Cell Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
OPC1 is an oligodendrocyte progenitor cell therapy that is currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries (SCI). Oligodendrocyte progenitor cells (OPCs) are naturally-occurring precursors to the cells which provide electrical insulation for nerve axons in the form of a myelin sheath. SCI occurs when the spinal cord is subjected to a severe crush or contusion ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Developed by Dr. Stephen Neidle and his group at UCL, the G4 binding concept ...